De Novo Pharmaceuticals evolved from the drug design group of the Department of Pharmacology at the University of Cambridge. The company specializes in in-silico drug delivery and its business strategy is focused around SkelGen(TM) technology. De Novo has a product portfolio of drug design technologies that cover 5 areas of drug design namely Quasi2(TM), SiteExplorer(TM), SkelGen(TM), LibMaker(TM) and EasyDock. In 2005 the company raised nearly £19 M from two funding rounds from Venture Capital Investors.